PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Daclatasvir - Hepatitis C
PAD Profile : Daclatasvir - Hepatitis C
Keywords :
Hep C, NICE, cirrhosis, fibrosis, peginterferon alfa, ribavirin, sofosbuvir, METAVIR, HCV, hepatitis, antiviral
Brand Names Include :
Daklinza
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Boceprevir
- Ribavirin
- Sofosbuvir
- Glecaprevir/pibrentasvir
- Dasabuvir
- Elbasvir
- Nitazoxanide
- Paritaprevir
- Setrobuvir
- Sofosbuvir, daclatasvir and ribavirin
- Sofosbuvir and velpatasvir
- Asunaprevir and daclatasvir
- Beclabuvir
- Filibuvir
- Elbasvir/grazoprevir
- Ledipasvir/sofosbuvir
- Paritaprevir/ritonavir/ombitasvir
- Ritonavir
- Peginterferon alfa
- Sofosbuvir/velpatasvir/voxilaprevir
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
02 December 2015
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Implementation of NICE TA 364 - Daclatasvir is recommended by NICE guidance.
This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.
Treatment should remain with the specialist (RED) hospital only drug.
GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
Associated BNF Codes
05. Infections
05.03.03. Viral hepatitis